Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes

Pharmaceutical Research

Volumn 16, Issue 7, 1999, Pages 1010-1019

  Omelyanenko, Vladimir ^a   Kopečková, Pavla ^a   Prakash, Ramesh K ^b   Ebert, Charles D ^b   Kopeček, Jindřich ^a  

^a UNIVERSITY OF UTAH   (United States)

^b TheraTarget Inc   (United States)

Author keywords

Adriamycin; B cells; Cancer therapy; CD21 receptor; Doxorubicin; Drug carrier; HPMA copolymer; T cells; Targeting

Indexed keywords

DOXORUBICIN; DRUG CARRIER; EPITOPE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032772050     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018975414165     Document Type: Article

References (30)

1. D. Putnam and J. Kopeček. Polymer conjugates with anticanccr activity. Adv. Polym. Sci. 122:55-123 (1995).
2. H. Maeda, L. M. Seymour, and Y. Miyamoto. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:351-362 (1992).
3. R. Duncan, L. C. W. Seymour, L. Scarlett, J. B. Lloyd, P. Rejmanová, and J. Kopeček. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880:62-71 (1986).
4. B. Říhová, P. Kopečková, J. Strohalm, P. Rossmann, V. Větvička, and J. Kopeček. Antibody directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:100-114 (1988).
5. V. Omelyanenko, P. Kopečková, C. Gentry, J.-G. Shiah, and J. Kopeček. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. I. Influence of the methods of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target. 3:357-373 (1996).
6. G. B. Sigal, M. Mammen, G. Dahman, and G. M. Whitesides. Polyacrylamides bearing pendant sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J. Am. Chem. Soc. 118:3789-3800 (1996).
7. R. C. Rathi, P. Kopečková, and J. Kopeček. Biorecognition of sugar containing N-(2-hydroxypropyl)methacrylamide copolymers by immobilized lectin. Macromol. Chem. Phys. 198:1165- 1180 (1997).
8. A. V. Tersikh, J.-M. Le Doussal, R. Crameri, I. Fisch, J.-P. Mach, and A. V. Kajava, "Peptabody": A new type of high avidity binding protein. Proc. Natl. Acad. Sci. USA 94:1663-1668 (1997).
9. R. K. Jain, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:570-576 (1989).
10. N. L. Krinick, Y. Sun, D. Joyner, J. D. Spikes, R. C. Straight, and J. Kopeček. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomat. Sci., Polym. Ed. 5: 303-324 (1994).
11. σ and adriamycin. 25th Int. Symposium on Controlled Release of Bioactive Materials, Las Vegas, Nevada, June 21-24, 1998. Proceedings, pp. 95-96.
12. S. K. Hobs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607-4612 (1998).
13. G. R. Nemerow, R. A. Houghten, M. D. Moore, and N. R. Cooper. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369-377 (1989).
14. D. Watry, J. A. Hedrick, S. Siervo, G. Rhodes, J. J. Lamberti, J. D. Lambris, and C. D. Tsoukas. Infection of human thymocytes by Epstein-Barr virus. J. Exp. Med. 173:971-980 (1991).
15. J. Kopeček and P. Rejmanová. Enzymatically degradable bonds in synthetic polymers. In S. D. Bruck (ed.), Controlled Drug Delivery, CRC Press, Boca Raton, Florida, 1983, vol. I, pp. 81-124.
16. P. Rejmanová, J. Pohl, M. Baudyš, V. Kostka, and J. Kopeček. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:2009-2020 (1983).
17. J. Kopeček. Synthesis of tailor-made soluble polymeric carriers. In J. M. Anderson, S. W. Kim (eds.), Recent Advances in Drug Delivery Systems, Plenum Press, New York, NY, 1984, pp. 41-62.
18. M. B. Hansen, S. E. Nielsen, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growing/cell kill. J. Immunol. Meth. 119:203-210 (1989).
19. G. C. Salzman, J. M. Growell, J. C. Martin, et al. Cell identification by laser light scattering: Identification and separation of unstained leukocyte. Acta Cytol. (Praha) 19:374-377 (1975).
20. I. Vermes, C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using labeled Annexin V. J. Immun. Methods 184:39-51 (1995).
21. J. D. Lambris, V. S. Ganu, S. Hirani, and H. J. Muller-Eberhard. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc. Natl. Acad. Sci. U.S.A. 82:4235-4239 (1985).
22. J. Tanner, J. Weis, D. Fearon, Y. Whang, and E. Kieff. Epstein- Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203- 213 (1987).
23. C. D. Tsoukas and J. D. Lambris. Expression of EBV/C3d receptors on T cells. Immunology Today 14:56-59 (1993).
24. E. Fischer, C. Delibrias, and M. D. Kazatchkine. Expression of CR2 (the C3dg/EBV receptor, CD21 ) on normal human peripheral blood T lymphocytes. J. Immunol. 146:865-869 (1991).
25. G. Sauvageau, R. Stocco, S. Kasparian, and J. Menezes. Epstein- Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes. J. Gen. Virol. 71:379-386 (1990).
26. R. Rask, J. M. Rasmussen, H. V. Hansen, P. Bysted, and S. E. Svehag. Complement C3dg/Epstein-Barr virus receptor density on human B lymphocytes estimated by immunoenzymatic assay and immunocytochemistry. J. Clin. Lab. Immunol. 25:153-156 (1988).
27. J. A. Hedrick, D. Watry, C. Speiser, P. O'Donnell, J. D. Lambris, and C. D. Tsoukas. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. Eur. J. Immunol. 22:1123-1131 (1992).
28. R. Stocco, G. Sauvageau, and J. Menezes. Differences in Epstein- Barr virus (EBV) receptors expression on various human lymphoid targets and their significance to EBV-cell interactions. Virus Res. 11:209-225 (1988).
29. I. Muller, A. Jenner, G. Bruchelt, D. Niethammer, and B. Halliwell, Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 230:254-257 (1997).
30. R. K. Prakash, C. M. Clemens, C. D. Ebert, V. Omelyanenko, P. Kopečková, and J. Kopeček. Targeting of macromolecular pro- drugs to T-lymphocytes. 24th Intern. Symp. Contr. Rel. Bioact. Mater., July 15-19, 1997 Stockholm, Sweden; Proceedings, pp. 859-860.